These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22621923)

  • 1. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
    Chen Z; Vigueira PA; Chambers KT; Hall AM; Mitra MS; Qi N; McDonald WG; Colca JR; Kletzien RF; Finck BN
    J Biol Chem; 2012 Jul; 287(28):23537-48. PubMed ID: 22621923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beneficial metabolic effects of insulin sensitizers are not attenuated by mitochondrial pyruvate carrier 2 hypomorphism.
    Vigueira PA; McCommis KS; Hodges WT; Schweitzer GG; Cole SL; Oonthonpan L; Taylor EB; McDonald WG; Kletzien RF; Colca JR; Finck BN
    Exp Physiol; 2017 Aug; 102(8):985-999. PubMed ID: 28597936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
    Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
    Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.
    Higashi Y; Holder K; Delafontaine P
    J Biol Chem; 2010 Nov; 285(47):36361-8. PubMed ID: 20843793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obese mice lacking inducible nitric oxide synthase are sensitized to the metabolic actions of peroxisome proliferator-activated receptor-gamma agonism.
    Dallaire P; Bellmann K; Laplante M; Gélinas S; Centeno-Baez C; Penfornis P; Peyot ML; Latour MG; Lamontagne J; Trujillo ME; Scherer PE; Prentki M; Deshaies Y; Marette A
    Diabetes; 2008 Aug; 57(8):1999-2011. PubMed ID: 18458147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.
    Wu D; Eeda V; Undi RB; Mann S; Stout M; Lim HY; Wang W
    Mol Metab; 2021 Dec; 54():101363. PubMed ID: 34710641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss.
    Fukunaga T; Zou W; Rohatgi N; Colca JR; Teitelbaum SL
    J Bone Miner Res; 2015 Mar; 30(3):481-8. PubMed ID: 25257948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo.
    Ming Y; Hu X; Song Y; Liu Z; Li J; Gao R; Zhang Y; Mei H; Guo T; Xiao L; Wang B; Wu C; Xiao X
    PLoS One; 2014; 9(7):e102102. PubMed ID: 25004107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone Requires Hepatocyte PPARγ Expression to Promote Steatosis in Male Mice With Diet-Induced Obesity.
    Lee SM; Muratalla J; Diaz-Ruiz A; Remon-Ruiz P; McCann M; Liew CW; Kineman RD; Cordoba-Chacon J
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34417811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones.
    Benova A; Ferencakova M; Bardova K; Funda J; Prochazka J; Spoutil F; Cajka T; Dzubanova M; Balcaen T; Kerckhofs G; Willekens W; van Lenthe GH; Alquicer G; Pecinova A; Mracek T; Horakova O; Rossmeisl M; Kopecky J; Tencerova M
    Mol Metab; 2022 Nov; 65():101598. PubMed ID: 36103974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
    Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
    J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
    Choi JH; Banks AS; Kamenecka TM; Busby SA; Chalmers MJ; Kumar N; Kuruvilla DS; Shin Y; He Y; Bruning JB; Marciano DP; Cameron MD; Laznik D; Jurczak MJ; Schürer SC; Vidović D; Shulman GI; Spiegelman BM; Griffin PR
    Nature; 2011 Sep; 477(7365):477-81. PubMed ID: 21892191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo.
    Nakano R; Kurosaki E; Yoshida S; Yokono M; Shimaya A; Maruyama T; Shibasaki M
    Biochem Pharmacol; 2006 Jun; 72(1):42-52. PubMed ID: 16696951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81).
    Jeninga EH; Bugge A; Nielsen R; Kersten S; Hamers N; Dani C; Wabitsch M; Berger R; Stunnenberg HG; Mandrup S; Kalkhoven E
    J Biol Chem; 2009 Sep; 284(39):26385-93. PubMed ID: 19633298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Acetylfarnesylcysteine is a novel class of peroxisome proliferator-activated receptor γ ligand with partial and full agonist activity in vitro and in vivo.
    Bhalla K; Hwang BJ; Choi JH; Dewi R; Ou L; Mclenithan J; Twaddel W; Pozharski E; Stock J; Girnun GD
    J Biol Chem; 2011 Dec; 286(48):41626-41635. PubMed ID: 21979952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.